This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Jimenez-Vicioso A, Torres-Isidro V, Carreras-Delgado J. The interest of PET (Positron Emission Tomography) for urothelial tumors. Arch Esp Urol. 2004;57(3):337–47.
Hain SF. Positron emission tomography in uro-oncology. Cancer Imaging. 2005;5(1):1–7.
Kamel EM, Jichlinski P, Prior J, Delaloye A, et al. Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies. J Nucl Med. 2006;47(11):1803–7.
Lopez-Gandul S, Perez-Moure G, Garcia-Garzón JR, Soler M, Simó M, et al. Intravenous furosemide injection during 18F-FDG PET acquisition. J Nucl Med Technol. 2006;34(4):228–31.
Shvarts O, Han KR, Seltzer M, Pantuck AJ, Belldegrun AS. Positron emission tomography in urologic oncology. Cancer Control. 2002;9:335–42.
Hara T. 11C-Choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol. 2002;4:267–73.
Ramirez de Molina A, Penalva V, Lucas L, Lacal JC. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene. 2002;21:937–46.
Hara T, Kosaka N, Kishi H. Development of 18F-fluoroe- thylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med. 2002;43:187–99.
Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, et al. FDG-PET for preoperative staging of bladder cancer: Eur J Nucl Med Mol Imaging. 2005;32(12):1412–7.
Picchio M, Triber U, Beer A, Metz S, Bössner P, et al. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med. 2006;47(6):938–44.
Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med. 1997;24:615–20.
Koyama K, Okamura T, Kawabe J, et al. Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors. J Nucl Med. 2003;44:353–8.
Diehl M, Manolopoulou M, Risse J, et al. Urinary fluorine-18 fluorodeoxyglucose excretion with and without intravenous application of furosemide. Acta Med Austriaca. 2004;31:76–8.
Thorens B. Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes. Am J Physiol. 1996;270: G541–53.
Southworth R, Parry CR, Parkes HG, Medina RA, Garlick PB. Tissue-specific differences in 2-fluoro-2-deoxyglucose metabolism beyond FDG-6-P: a 19F NMR spectroscopy study in the rat. NMR Biomed. 2003;16:494–502.
Miyakita H, Tokunaga M, Onda H, et al. Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol. 2002;9:15–8.
Kuczyk M, Turkeri L, Hammerer P, Ravery V, European Society for Oncological Urology. Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer? Eur Urol. 2003;44:57–64.
Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today: a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003;21:690–6.
Vazina A, Dugi D, Shariat SF, Evans J, Link R, Lerner SP. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J Urol. 2004;171:1830–4.
Picchio M, Messa C, Landoni C, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol. 2003;169:1337–40.
Liu IJ, lai YH, Espiritu JI, Segall GM, Srinivas S, et al. Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Urol Int. 2006;77(1):69–75.
Kaneta T, Hakamatsuka T, Yamada T, Takase K, Sato A, et al. FDG PET in solitary metastasic and secondary tumor of the kidney. Ann Nucl Med. 2006;20(1):79–82.
de Jong IJ, Pruim J, Elsinga PH, Jongen MM, Mensink HJ, Vaalburg W. Visualisation of bladder cancer using (11)C-choline PET: first clinical experience. Eur J Nucl Med Mol Imaging. 2002;29(10):1283–8.
Kotzerke J, Prang J, Neumaier B, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med. 2000;27:1415–9.
de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med. 2003;44:331–5.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag London Limited
About this chapter
Cite this chapter
Palou, J., Carrió, I., Villavicencio, H. (2009). Urothelial Cell Carcinoma in Upper Urinary Tract – Role of PET Imaging. In: de la Rosette, J.J., Manyak, M.J., Harisinghani, M.G., Wijkstra, H. (eds) Imaging in Oncological Urology. Springer, London. https://doi.org/10.1007/978-1-84628-759-6_13
Download citation
DOI: https://doi.org/10.1007/978-1-84628-759-6_13
Publisher Name: Springer, London
Print ISBN: 978-1-84628-514-1
Online ISBN: 978-1-84628-759-6
eBook Packages: MedicineMedicine (R0)